(CGEN) Compugen Ltd. Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CGEN) Compugen Ltd. Complete Analysis Pack
From Overview to Strategy Blueprint
This Compugen Ltd. Porter's Five Forces Analysis helps you assess competitive pressure, industry attractiveness, and the forces shaping the company’s position. The page already shows a real preview of the report content, so you can review it before buying. Purchase the full version to get the complete ready-to-use analysis.
Suppliers Bargaining Power
Specialized biologics inputs
Compugen Ltd. relies on specialized suppliers for antibodies, cell lines, assay materials, and GMP manufacturing, and these inputs are not easy to swap. That narrows the vendor pool and gives suppliers leverage on price, lead times, and batch priority. In biologics, qualified GMP capacity stays tight, so delays or cost hikes can hit programs fast.
CDMO dependence
Compugen’s late-stage and clinical biologics work depends on a small set of CDMOs, so a switch can raise costs, slip timelines, and force technical trade-offs. That pressure is sharper for complex antibody and bispecific programs, where process changes can ripple through scale-up and comparability work. In 2025/2026, this kind of supplier lock-in can become a direct negotiating lever.
Clinical trial service concentration
Compugen depends on a small set of CROs, clinical labs, and regulatory specialists to run oncology studies across multiple geographies. When only a few experienced providers can support complex protocols, they can press for higher fees and tighter terms. That power rises when oncology trial slots are scarce, because delays can slow enrollment and push back readouts.
Research reagent scarcity
Research reagents create a high supplier squeeze for Compugen Ltd. Early discovery and translational work depends on niche antibodies, biomarkers, and assay platforms, and these often come from a small set of vendors with patented methods or deep technical know-how.
That makes switching costly and slow, since revalidation can disrupt timelines and data comparability.
- Few qualified reagent suppliers
- High IP and know-how barriers
- Switching raises cost and delay
Talent as a critical supplier
In biotech, skilled scientists and clinical-development experts act like critical suppliers, and Compugen Ltd. must compete for them across Israel, the US, and Europe. This makes talent scarce and expensive, especially in immuno-oncology.
When the labor pool is tight, compensation rises and hiring slows, which can strain Compugen Ltd.’s R&D pace and reduce staffing flexibility. The risk is highest for niche roles that need deep trial and target-discovery experience.
- High-skill talent has real supplier power.
- Scarcity can lift pay and delay hiring.
- Cross-border competition tightens retention.
Compugen Faces Strong Supplier Leverage in 2025/2026
Compugen Ltd.’s supplier power is high because key inputs like GMP capacity, CRO support, and niche reagents come from a small vendor pool. Switching is slow and costly, so suppliers can press on price, timing, and terms. In 2025/2026, tight biologics capacity and scarce oncology trial slots keep that leverage elevated.
Compugen Ltd. also faces labor supplier power: skilled immuno-oncology and clinical staff are scarce across Israel, the US, and Europe. That raises pay and slows hiring when competition for talent intensifies.
| Driver | Power |
|---|---|
| GMP/CDMO capacity | High |
| Specialized reagents | High |
| Clinical talent | High |
What is included in the product
Detailed Word Document
Uncovers how suppliers, buyers, rivals, new entrants, and substitutes shape Compugen Ltd.’s competitive position.
Customizable Excel Spreadsheet
Quickly spot Compugen Ltd.’s five-force pressures in one simple view, cutting guesswork and saving hours of analysis.
Reference Sources
Compugen Ltd. Reference Sources provide a credible, traceable evidence base that speeds diligence and supports confident decision-making.
Customers Bargaining Power
Pharma partners hold leverage
Compugen’s bargaining power is low because its main "customers" are big pharma partners, not end buyers. Bayer, Bristol Myers Squibb, and AstraZeneca can push for milestone-heavy deals, strict data rights, and easy exits. In biotech partnering, that leverage is common: upfront cash is often small versus total deal value, so partners control most economics.
Payment tied to clinical success
Compugen Ltd. mainly earns collaboration revenue through milestones, licensing fees, and royalties, so payment often depends on clinical progress. If a partnered program stalls or weakens, customers can delay or cut payments, which gives them real leverage over near-term cash flow. That makes customer bargaining power high, because success in the clinic directly drives Compugen Ltd. revenue.
Few direct buyers for assets
Compugen Ltd. has few direct buyers for early-stage immuno-oncology assets, which can support pricing in licensing talks. But large pharma still has many substitute targets and can spread R&D across broad pipelines; in 2025, Compugen reported only $0.3 million in revenue, showing how dependent it is on partner demand. So buyer power stays moderate to high.
High due diligence standards
Customers have high bargaining power because they demand clear efficacy and safety proof before they fund a program, and they can drop anything that looks redundant or scientifically weak. For Compugen Ltd., that means every update must sharpen the pipeline story and show why a target is better than other immuno-oncology bets.
- Strong data or capital walks.
- Clear differentiation is mandatory.
- Pipeline story drives customer trust.
Patients do not directly set terms
Patients influence uptake, but they do not negotiate with Compugen Ltd.; reimbursement gates, physicians, and payer review do. In 2025, about 66 million Americans were in Medicare, so coverage rules and prior auth still shape oncology demand more than patient choice. That keeps customer power centered in insurers and care providers, not end users.
- Patients affect adoption, not pricing.
- Payers and physicians control access.
- Reimbursement scrutiny weakens direct buyer power.
Compugen’s Big Pharma Partners Hold the Pricing Power
Compugen Ltd.’s customer power is high because a few big pharma partners control milestones, exits, and data rights. In 2025, Compugen Ltd. reported just $0.3 million of revenue, so partner decisions can swing cash flow fast. That makes pricing and deal terms depend more on buyer demand than on Compugen Ltd.’s leverage.
| Metric | 2025 |
|---|---|
| Revenue | $0.3M |
| Core buyers | Big pharma |
| Buyer power | High |
Preview Before You Purchase
Compugen Ltd. Porter's Five Forces Analysis
This preview shows the exact Compugen Ltd. Porter's Five Forces Analysis you’ll receive after purchase—no placeholders, no surprises. The document is fully written, professionally formatted, and ready for immediate use the moment your payment is complete. What you’re seeing here is the same final file that will be available for download.
Rivalry Among Competitors
Intense immuno-oncology competition
Compugen faces intense immuno-oncology rivalry: dozens of well-funded biotech and pharma peers are chasing checkpoint inhibitors, bispecifics, and myeloid targets, so scientific and clinical differentiation is hard. Merck’s Keytruda still posted $25.1 billion in 2023 sales, showing how large the reward is and how crowded the field remains. That scale keeps pressure high on Compugen to prove clear efficacy, safety, and biomarker fit.
Large pharma dominates key spaces
Large pharma dominates oncology: Merck’s KEYTRUDA brought in $29.5 billion in 2024, and Roche’s oncology unit stayed above CHF 20 billion, giving them cash, trial reach, and deal power Compugen Ltd. can’t match.
These firms can run many programs at once, so one failure does not slow them down. Compugen Ltd., as a clinical-stage company, faces rivals that can absorb higher attrition and keep pushing new candidates.
That scale makes rivalry intense and price pressure real, especially in crowded immuno-oncology and checkpoint spaces.
Pipeline overlap with partners and peers
Pipeline overlap is high: TIGIT, PD-1 combinations, and new immune checkpoints are crowded areas with many peers chasing the same biology. If a rival posts better efficacy or fewer safety issues in late-stage trials, Compugen Ltd.'s assets can lose deal value fast. This raises rivalry, because similar mechanisms across companies make differentiation harder and partner choice more price-sensitive.
Need for clinical differentiation
In oncology, even a 5% to 10% edge in response or tolerability can decide uptake, so Compugen Ltd. must show clear clinical value against many rivals. The pressure is high because each readout can shift partnering value, pricing power, and trial momentum fast. One weak signal can leave a program stranded in a crowded market.
- Small efficacy gaps can change sales.
- Tolerability drives prescriber choice.
- Fast trials raise R&D risk.
Scientific competition for platform credibility
Competitive rivalry is high because platform credibility matters as much as single-drug results. Compugen’s ties with Bayer, Bristol Myers Squibb, and Johns Hopkins support its target biology and translational story, but rivals with cleaner clinical data can still win investor and partner attention fast.
- Credibility drives deal flow.
- Clinical data can reset attention quickly.
- Partnerships help, but proof wins.
Compugen Faces Fierce Immuno-Oncology Competition
Competitive rivalry is high in immuno-oncology, where many biotech and pharma peers chase similar targets, so small data gaps can swing partner value fast. Compugen Ltd. must beat rivals on efficacy, safety, and biomarker fit, or its programs lose attention. Big pharma scale keeps trial and deal pressure intense.
| Signal | Impact |
|---|---|
| Target crowding | High |
| Trial scale gap | Wide |
| Data edge needed | Small |
Substitutes Threaten
Alternative oncology modalities
Alternative oncology options are strong substitutes: chemotherapy, targeted therapy, radiation, surgery, and other immunotherapies all compete for the same patient. In 2025, the cancer market still had broad treatment choice, so if Compugen Ltd. has unclear efficacy, physicians can switch fast. This wide toolbox also caps pricing power and slows adoption versus proven standards.
Other checkpoint mechanisms
Threat of substitutes is high: if COM701, COM902, or bapotulimab underdeliver, doctors can stay with entrenched checkpoint drugs like PD-1/PD-L1 or shift to rival pathways. The field is crowded, with more than 10 approved PD-1/PD-L1 therapies and many late-stage programs, so a stronger Phase 2/3 readout elsewhere can quickly pull use away.
Combination regimen substitutes
Compugen Ltd.'s assets are usually tested with PD-1 inhibitors, and that matters because there are many competing combo regimens in the market. When dozens of oncology partners can pair a drug with established PD-1 backbones, no single mix wins by default. So Compugen needs clear gains in response rate or safety to stand out.
Cell and gene therapy alternatives
Cell and gene therapy is a real substitute threat for Compugen Ltd. in some advanced cancers, because 6 FDA-approved CAR-T therapies and marketed bispecific T-cell engagers already compete for the same relapsed or hard-to-treat patients. In selected settings, these options can deliver deeper responses than checkpoint-based drugs, so they can take share where efficacy matters most.
That said, they are still used in narrower patient groups, often with strict eligibility and higher treatment complexity, so they do not replace checkpoint therapies across all tumors. The substitute pool is still widening as more cell and gene therapy programs move from trials into practice.
- 6 FDA-approved CAR-T therapies
- Bispecifics already market-ready
- Best in selected cancer settings
- Raises direct patient-level competition
Watchful waiting and standard care
In Compugen Ltd.'s solid-tumor programs, watchful waiting and standard care remain practical substitutes when experimental therapies do not clearly beat current outcomes. This is strongest in early-stage clinical development, where doctors can keep using established pathways instead of taking extra risk on unproven drugs.
- Standard care already exists.
- Early data must show clear benefit.
- Weak signals reduce adoption fast.
High Substitute Threat Pressures Company Name's Oncology Pipeline
Threat of substitutes for Company Name is high because oncology doctors can use chemotherapy, surgery, radiation, PD-1/PD-L1 drugs, CAR-T, or bispecifics instead. In 2025, more than 10 PD-1/PD-L1 therapies were already approved, and 6 FDA-approved CAR-Ts added more pressure in narrow but high-value cancers.
If COM701, COM902, or bapotulimab do not show clear benefit, physicians can stay with standard care or switch to stronger rival regimens fast. That keeps pricing power low and adoption tied to clean Phase 2/3 data.
| Substitute | Latest number | Why it matters |
|---|---|---|
| PD-1/PD-L1 drugs | 10+ approved | Direct backbone rival |
| CAR-T therapies | 6 FDA-approved | Strong in selected cancers |
Entrants Threaten
High capital requirements
Entering immuno-oncology needs huge cash for discovery, GMP manufacturing, and multi-year trials. A single drug can cost over $1 billion to bring to market, and Phase 3 studies can run into the tens or hundreds of millions. For Compugen Ltd, that scale of spend blocks most new entrants and makes the threat of new entrants low.
Regulatory and development hurdles
Biologics face strict safety, efficacy, and manufacturing rules, and the path is long: drug development often takes 10-15 years, while only about 1 in 10 candidates reaches approval. For Compugen Ltd., that means new entrants need deep cash, strong CMC (chemistry, manufacturing, and controls) systems, and patience. These hurdles make casual competition unlikely.
IP and know-how barriers
Compugen Ltd.'s IP, platform biology, and partner-backed know-how make entry hard to copy fast. New entrants need credible target biology, translational skill, and years of tacit learning, while patents and data rights lift the cost and time to compete. That keeps the threat of new entrants low.
Access to partners is limited
Access to partners stays a real barrier for Compugen Ltd. Top-tier pharma groups get many licensing pitches, so they back teams with strong data, clear clinical readouts, and lower execution risk. New entrants without that proof often can’t secure collaboration funding or development support, which helps established players with visible validation hold their edge.
- Selective pharma deal flow raises entry barriers
- Weak data makes funding harder to win
- Validation helps incumbents keep partner access
Talent and trial execution constraints
Launching a Compugen Ltd. oncology biotech is hard because elite scientists, CRO slots, investigators, and patients are all scarce and already booked. Even if basic science looks easy to copy, trial execution is not: Compugen Ltd. still has to compete for the same scarce oncology sites and patient pools used by large-cap peers. That raises time, cost, and failure risk, so the threat of new entrants stays moderate rather than high.
- Elite talent is tightly contested
- CRO capacity is a bottleneck
- Patient recruitment slows trials
- Execution barriers protect incumbents
Compugen Faces Low New-Entrant Threat Amid Biotech’s High Barriers
Threat of new entrants for Compugen Ltd. stays low. Biotech entry needs huge capital, long trials, and scarce IP, while drug development success is still near 10%. New players also need FDA-grade CMC, top talent, and partner trust, which slows entry and raises failure risk.
| Barrier | Latest signal |
|---|---|
| Drug cost | Over $1B |
| Approval odds | About 10% |
| Timeline | 10-15 years |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.